• $68.5M
    Market Cap
  • 35.34%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 53
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics announced preclinical data showing strong synergies between its lead assets ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) when combined with anti-PD-L1 checkpoint inhibitors and ADC payloads. The company will present three posters at the AACR 2026 Annual Meeting in San Diego, demonstrating potent efficacy and durable immune memory in combination therapies, supporting potential frontline clinical development opportunities.

04/17/2026, 4:00 PM • GlobeNewswire

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics announced three poster presentations at the 2026 AACR Annual Meeting showcasing preclinical data demonstrating strong synergy of ACR-368 (CHK1/2 inhibitor) with Topoisomerase 1 inhibitor ADC payloads, and synergy of both ACR-368 and ACR-2316 (WEE1/PKMYT1 inhibitor) with immune checkpoint inhibitors. The data highlight the company's AP3 platform's ability to identify therapeutic candidates and combinations with clinical potential.

03/17/2026, 5:54 PM • GlobeNewswire

Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight

A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.

07/15/2025, 1:00 PM • GlobeNewswire

Peers

  • RLMD
    RELMADA THERAPEU
    $6.30-1.87%
    Market Cap$756.3M
    1-Year Change+820.69%
  • UNCY
    UNICYCIVE THERAP
    $7.40+2.35%
    Market Cap$197.0M
    1-Year Change-5.24%
  • CBUS
    CIBUS-A
    $1.48+6.19%
    Market Cap$109.9M
    1-Year Change-50.36%
  • BMEA
    BIOMEA FUSION
    $1.34-2.19%
    Market Cap$99.8M
    1-Year Change-44.98%
  • TCRX
    TSCAN THERAPEUT
    $0.96-2.05%
    Market Cap$66.0M
    1-Year Change-44.00%
  • PMVP
    PMV PHARMA
    $1.16-1.69%
    Market Cap$64.0M
    1-Year Change+28.36%
  • ATYR
    ATYR PHARMA
    $0.51-1.88%
    Market Cap$53.2M
    1-Year Change-90.35%
  • IMUX
    IMMUNIC
    $14.15-3.35%
    Market CapN/A
    1-Year Change+100.44%
  • VXRT
    Vaxart
    $0.41-34.68%
    Market CapN/A
    1-Year Change+48.75%

Statistics

More
Day Range
$1.52
$1.60
$1.57
1-Year Range
$1.16
$3.01
$1.57
Latest Close$1.57
Change
+$0.01 (+0.64%)
Volume629,809
Market Cap$68.5M
Shares Outstanding42.8M
P/E (TTM)-0.80
Diluted EPS (TTM)-$2.00
Enterprise Value$34.4M

Information as of 06/02/2026

Company Profile

ACRIVON THERAPEUTICS INC
https://acrivon.com
$68.5M
Market Cap
-$77.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
480 Arsenal Way, Watertown, MA, United States, 02472
617 207 8979

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Key Executives

  • Peter Blume-Jensen
  • Kristina Masson
  • Eric J. Devroe
  • Mary-Alice Miller
  • Erick Gamelin

Current Ownership Distribution

  • Institutions117.2M (82.54%)
  • Mutual Funds13.4M (9.46%)
  • Insiders11.4M (8.00%)
  • Other0 (0.00%)